175 related articles for article (PubMed ID: 29191752)
1. The use of chemogenetic approaches to study the physiological roles of muscarinic acetylcholine receptors in the central nervous system.
Bradley SJ; Tobin AB; Prihandoko R
Neuropharmacology; 2018 Jul; 136(Pt C):421-426. PubMed ID: 29191752
[TBL] [Abstract][Full Text] [Related]
2. Developing chemical genetic approaches to explore G protein-coupled receptor function: validation of the use of a receptor activated solely by synthetic ligand (RASSL).
Alvarez-Curto E; Prihandoko R; Tautermann CS; Zwier JM; Pediani JD; Lohse MJ; Hoffmann C; Tobin AB; Milligan G
Mol Pharmacol; 2011 Dec; 80(6):1033-46. PubMed ID: 21880827
[TBL] [Abstract][Full Text] [Related]
3. Physiological roles of CNS muscarinic receptors gained from knockout mice.
Thomsen M; Sørensen G; Dencker D
Neuropharmacology; 2018 Jul; 136(Pt C):411-420. PubMed ID: 28911965
[TBL] [Abstract][Full Text] [Related]
4. Allosteric modulators targeting CNS muscarinic receptors.
Bock A; Schrage R; Mohr K
Neuropharmacology; 2018 Jul; 136(Pt C):427-437. PubMed ID: 28935216
[TBL] [Abstract][Full Text] [Related]
5. DREADDs (designer receptors exclusively activated by designer drugs): chemogenetic tools with therapeutic utility.
Urban DJ; Roth BL
Annu Rev Pharmacol Toxicol; 2015; 55():399-417. PubMed ID: 25292433
[TBL] [Abstract][Full Text] [Related]
6. Muscarinic receptor oligomerization.
Marsango S; Ward RJ; Alvarez-Curto E; Milligan G
Neuropharmacology; 2018 Jul; 136(Pt C):401-410. PubMed ID: 29146505
[TBL] [Abstract][Full Text] [Related]
7. Muscarinic receptor subtype distribution in the central nervous system and relevance to aging and Alzheimer's disease.
Lebois EP; Thorn C; Edgerton JR; Popiolek M; Xi S
Neuropharmacology; 2018 Jul; 136(Pt C):362-373. PubMed ID: 29138080
[TBL] [Abstract][Full Text] [Related]
8. Engineered G-protein Coupled Receptors are Powerful Tools to Investigate Biological Processes and Behaviors.
Nichols CD; Roth BL
Front Mol Neurosci; 2009; 2():16. PubMed ID: 19893765
[TBL] [Abstract][Full Text] [Related]
9. Viral Vector Delivery of DREADDs for CNS Therapy.
Pickering CA; Mazarakis ND
Curr Gene Ther; 2021; 21(3):191-206. PubMed ID: 33573551
[TBL] [Abstract][Full Text] [Related]
10. How structure informs and transforms chemogenetics.
Roth BL
Curr Opin Struct Biol; 2019 Aug; 57():9-16. PubMed ID: 30818201
[TBL] [Abstract][Full Text] [Related]
11. Engineered GPCRs as tools to modulate signal transduction.
Pei Y; Rogan SC; Yan F; Roth BL
Physiology (Bethesda); 2008 Dec; 23():313-21. PubMed ID: 19074739
[TBL] [Abstract][Full Text] [Related]
12. Muscarinic acetylcholine receptors as CNS drug targets.
Langmead CJ; Watson J; Reavill C
Pharmacol Ther; 2008 Feb; 117(2):232-43. PubMed ID: 18082893
[TBL] [Abstract][Full Text] [Related]
13. Generation of designer receptors exclusively activated by designer drugs (DREADDs) using directed molecular evolution.
Pei Y; Dong S; Roth BL
Curr Protoc Neurosci; 2010 Jan; Chapter 4():Unit 4.33. PubMed ID: 20066658
[TBL] [Abstract][Full Text] [Related]
14. Clozapine N-Oxide Administration Produces Behavioral Effects in Long-Evans Rats: Implications for Designing DREADD Experiments.
MacLaren DA; Browne RW; Shaw JK; Krishnan Radhakrishnan S; Khare P; España RA; Clark SD
eNeuro; 2016; 3(5):. PubMed ID: 27822508
[TBL] [Abstract][Full Text] [Related]
15. The first structure-activity relationship studies for designer receptors exclusively activated by designer drugs.
Chen X; Choo H; Huang XP; Yang X; Stone O; Roth BL; Jin J
ACS Chem Neurosci; 2015 Mar; 6(3):476-84. PubMed ID: 25587888
[TBL] [Abstract][Full Text] [Related]
16. Novel designer receptors to probe GPCR signaling and physiology.
Wess J; Nakajima K; Jain S
Trends Pharmacol Sci; 2013 Jul; 34(7):385-92. PubMed ID: 23769625
[TBL] [Abstract][Full Text] [Related]
17. Effects of clozapine-N-oxide and compound 21 on sleep in laboratory mice.
Traut J; Mengual JP; Meijer EJ; McKillop LE; Alfonsa H; Hoerder-Suabedissen A; Song SH; Fehér KD; Riemann D; Molnar Z; Akerman CJ; Vyazovskiy VV; Krone LB
Elife; 2023 Mar; 12():. PubMed ID: 36892930
[TBL] [Abstract][Full Text] [Related]
18. Regulation and trafficking of muscarinic acetylcholine receptors.
Zenko D; Hislop JN
Neuropharmacology; 2018 Jul; 136(Pt C):374-382. PubMed ID: 29138081
[TBL] [Abstract][Full Text] [Related]
19. Utilizing Designed Receptors Exclusively Activated by Designer Drug Chemogenetic Tools to Identify Beneficial G Protein-Coupled Receptor Signaling for Fibrosis.
Zhang J; Vardy E; Muise ES; Wang TM; Visconti R; Vadlamudi A; Pinto S; Peier AM
J Pharmacol Exp Ther; 2020 Nov; 375(2):357-366. PubMed ID: 32848074
[TBL] [Abstract][Full Text] [Related]
20. Design and functional characterization of a novel, arrestin-biased designer G protein-coupled receptor.
Nakajima K; Wess J
Mol Pharmacol; 2012 Oct; 82(4):575-82. PubMed ID: 22821234
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
